Figure 3.
Increased immunohistochemical expression of ASNS with clinical progression of prostate cancer. H&E-stained sections showing castration-resistant adenocarcinoma (A), castration-resistant small-cell carcinoma (B), and hormone-sensitive high-grade prostate carcinoma (C) and ASNS immunostaining of these samples (D–F, respectively), with relative immunoexpression of different groups (G). The x denotes outlier data points.